Patents by Inventor Manuela Mally
Manuela Mally has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240316172Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: ApplicationFiled: January 29, 2024Publication date: September 26, 2024Inventors: Jeroen GEURTSEN, Jan Theunis POOLMAN, Kellen Cristhina FAE, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
-
Patent number: 12076385Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.Type: GrantFiled: September 23, 2022Date of Patent: September 3, 2024Assignees: Janssen Pharmaceuticals, Inc., GlaxosSmithKline Biologicals S.A.Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
-
Publication number: 20240287568Abstract: Described herein are compositions and methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.Type: ApplicationFiled: January 4, 2024Publication date: August 29, 2024Inventors: Amirreza Faridmoayer, Manuela Mally, Rainer Follador
-
Patent number: 11931405Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: GrantFiled: July 28, 2022Date of Patent: March 19, 2024Assignees: GlaxoSmithKline Biologicals S.A.Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Publication number: 20240067714Abstract: The present disclosure provides monoclonal antibodies (e.g., anti-TNF? antibodies) having Fab sialylation, and, in some aspects, Fab sialylation in combination with an afucosylated Fc. Such antibodies having improved immunogenicity profiles and related advantages. Such glycan modifications will improve current treatments and allow a better quality of life for patients. Accordingly, such monoclonal antibodies are useful for treating and preventing various diseases.Type: ApplicationFiled: September 13, 2021Publication date: February 29, 2024Applicant: LIMMATECH BIOLOGICS AGInventors: Manuela MALLY, Amirreza FARIDMOAYER, Rainer FOLLADOR, Jonathan Albert BACK
-
Patent number: 11913051Abstract: Described herein are compositions and methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.Type: GrantFiled: June 28, 2018Date of Patent: February 27, 2024Assignee: LimmaTech Biologics AGInventors: Amirreza Faridmoayer, Manuela Mally, Rainer Follador
-
Publication number: 20230364214Abstract: Provided herein is an E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.Type: ApplicationFiled: April 24, 2023Publication date: November 16, 2023Inventors: Michael T. KOWARIK, Michael L. WETTER, Stefan J. KEMMLER, Micha A. HÄUPTLE, Veronica GAMBILLARA, Manuela MALLY
-
Publication number: 20230287327Abstract: The present application relates to Leishmania cells genetically engineered such that the formation of an O-linked GlcNAc on a polypeptide in the Leishmania cell is reduced or eliminated. The formation of the O-linked GlcNAc may be catalyzed in the Leishmania cell prior to said genetic engineering by at least one N-acetylglucosamine (GlcNAc)-transferase. Also provided herein are methods of making a polypeptide using a Leishmania cell described herein and polypeptides produced by the methods provided herein.Type: ApplicationFiled: January 7, 2021Publication date: September 14, 2023Applicant: LIMMATECH BIOLOGICS AGInventors: Manuela MALLY, Amirreza FARIDMOAYER, Rainer FOLLADOR, Anke Judith HARSMAN
-
Patent number: 11738076Abstract: Provided herein is an E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.Type: GrantFiled: February 2, 2021Date of Patent: August 29, 2023Inventors: Michael T. Kowarik, Michael L. Wetter, Stefan J. Kemmler, Micha A. Häuptle, Veronica Gambillara, Manuela Mally
-
Publication number: 20230190926Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).Type: ApplicationFiled: October 6, 2022Publication date: June 22, 2023Inventors: Jeroen GEURTSEN, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Jan Theunis POOLMAN, Kellen Cristhina FAE, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
-
Publication number: 20230118878Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: ApplicationFiled: July 28, 2022Publication date: April 20, 2023Inventors: Jeroen GEURTSEN, Jan Theunis POOLMAN, Kellen Cristhina FAE, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
-
Publication number: 20230062987Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.Type: ApplicationFiled: September 23, 2022Publication date: March 2, 2023Inventors: Jan Theunis POOLMAN, Bert JACQUEMYN, Darren Robert ABBANAT, Patricia Ibarra YON, Peter Wilhelmus Maria HERMANS, Michael Thomas KOWARIK, Michael Lukas WETTER, Stefan Jochen KEMMLER, Micha Andres HÄUPTLE, Veronica Gambillara FONCK, Manuela MALLY
-
Publication number: 20230048847Abstract: The present application relates to a method of recombinantly engineering a Leishmania cell that involves homologous recombination of DNA fragments. Further provided herein are Leishmania cells recombinantly engineered using the method provided herein. Also provided herein are methods of making a polypeptide using a Leishmania cell described herein and polypeptides produced by the methods provided herein.Type: ApplicationFiled: January 7, 2021Publication date: February 16, 2023Applicant: LIMMATECH BIOLOGICS AGInventors: Manuela MALLY, Amirreza FARIDMOAYER, Fabio SERVENTI, Rainer FOLLADOR, Anke Judith HARSMAN
-
Patent number: 11491220Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).Type: GrantFiled: March 18, 2020Date of Patent: November 8, 2022Assignees: Janssen Pharmaceuticals, Inc.Inventors: Jeroen Geurtsen, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Jan Theunis Poolman, Kellen Cristhina Fae, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Patent number: 11484582Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.Type: GrantFiled: February 4, 2020Date of Patent: November 1, 2022Assignees: Janssen Pharmaceuticals, Inc.Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
-
Patent number: 11446370Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: GrantFiled: March 18, 2020Date of Patent: September 20, 2022Assignees: Janssen Pharmaceuticals, Inc., GlaxoSmithKline Biologicals S.A.Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Publication number: 20220242919Abstract: Described herein are methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.Type: ApplicationFiled: December 17, 2021Publication date: August 4, 2022Inventors: Michael L. Wetter, Michael T. Kowarik, Amirreza Faridmoayer, Manuela Mally, Christian A. Lizak, Markus Aebi, Chia-wei Lin, Ivan Hang, Timothy Keys
-
Patent number: 11236136Abstract: Described herein are methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.Type: GrantFiled: November 30, 2016Date of Patent: February 1, 2022Assignees: LIMMATECH BIOLOGICS AG, EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRICHInventors: Michael L. Wetter, Michael T. Kowarik, Amirreza Faridmoayer, Manuela Mally, Christian A. Lizak, Markus Aebi, Chia-wei Lin, Ivan Hang, Timothy Keys
-
Publication number: 20210332403Abstract: Described herein are compositions and methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.Type: ApplicationFiled: June 28, 2018Publication date: October 28, 2021Inventors: Amirreza Faridmoayer, Manuela Mally, Rainer Follador
-
Publication number: 20210154286Abstract: Provided herein is an E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.Type: ApplicationFiled: February 2, 2021Publication date: May 27, 2021Inventors: Michael T. KOWARIK, Michael L. WETTER, Stefan J. KEMMLER, Micha A. HÄUPTLE, Veronica GAMBILLARA, Manuela MALLY